Blood Sugar Control After Switching to Once-Weekly Insulin Icodec in Type 2 Diabetes
Observes adults with type 2 diabetes who switch from daily insulin to insulin icodec.
Plain-language title generated from the registry record
Registry title: Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin Icodec
Key facts
- Where
- Beijing, Chongqing, Harbin, Huai'an, Jiangmen, Jinan, Langfang, Lanzhou, Nanchang, Nanjing, Shanghai, Shenyang, Shiyan, Suzhou, and Urumuqi, ChinaSee the 15 sites
Where in China
- Beijing HospitalBeijing, ChinaNo longer taking part
- The Second Affiliated Hospital of Chongqing Medical University-EndocrinologyChongqing, ChinaNo longer taking part
- Heilongjiang Provincial HospitalHarbin, ChinaNo longer taking part
- NIS-Huai'an First People's Hospital-EndocrinologyHuai'an, ChinaNo longer taking part
- The People's Hospital of JiangMenJiangmen, ChinaNo longer taking part
- Shandong Provincial HospitalJinan, ChinaNo longer taking part
- Hebei Petrochina Central HospitalLangfang, ChinaNo longer taking part
- Gansu Provincial People's HospitalLanzhou, ChinaNo longer taking part
- The Second Affiliated Hospital of Nanchang UniversityNanchang, ChinaNo longer taking part
- NIS-Nanjing Jiangning Hospital-EndocrinologyNanjing, ChinaNo longer taking part
- Tongren Hospital Shanghai Jiao Tong University School Of MedicineShanghai, ChinaNo longer taking part
- The Fifth People's Hospital of ShenyangShenyang, ChinaNo longer taking part
- Shiyan City People's HospitalShiyan, ChinaNo longer taking part
- The Second Affiliated Hospital of Soochow UniversitySuzhou, ChinaNo longer taking part
- The First Affiliated Hospital of Xinjiang Medical UniversityUrumuqi, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07658417
- Record updated
- 15 September 2026
- Original description
The purpose of this study is to investigate the use of insulin icodec in the real-world setting in a population that broadly reflects people living with T2D and for whom switching to a once-weekly insulin icodec has been deemed relevant and beneficial by the treating physician. The study will last for approximately 30 weeks.Read full original descriptionShow less
A Real-world, Multi-centre, Prospective, Non-interventional, Single-arm Study Investigating Glycaemic Control, Treatment Satisfaction and Adherence Associated With the Switch From Daily Basal Insulin to Insulin Icodec in People Living With Type 2 Diabetes in China
The purpose of this study is to investigate the use of insulin icodec in the real-world setting in a population that broadly reflects people living with T2D and for whom switching to a once-weekly insulin icodec has been deemed relevant and beneficial by the treating physician. The study will last for approximately 30 weeks.
Inclusion: Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to protocol); The decision to initiate treatment with commercially available insulin icodec has been made by the participant/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include participant in this study; Male or female, age above or equal to 18 years at the time of signing informed consent; Diagnosed with T2D greater than or equal to (≥) 1 year before signing informed consent; Treated with once- or twice-daily basal insulin injections ≥ 6 months before signing informed consent. Any other antidiabetic medications are allowed, except for bolus insulin during the 90 days prior to switching to icodec for a period of 14 days or more; Available glycated haemoglobin (HbA1c) within 90 days prior to the 'Initiation visit' (V1) or HbA1c measurement taken in relation with the 'Initiation visit' (V1) if in line with local clinical practice; Treatment-naïve to once-weekly insulin prior to the 'Initiation Visit' (V1).
Exclusion: Previous participation in this study. Participation is defined as having given informed consent in this study; Treatment with any investigational drug within 30 days prior to enrolment into study; Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.